Kenneth Hoberman - 11 Jun 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Jun 2026, 16:12:38 UTC
Prior SEC filing
16 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kenneth Hoberman

Key filing fact

Kenneth Hoberman filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 12 Jun 2026.

Key facts

  • This page summarizes Kenneth Hoberman's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Jun 2026, 16:12.

Change

  • Previous filing in this sequence was filed on 16 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573722 Primary reporting owner

Hoberman Kenneth

Relationship
Director
Address
C/O NUVECTIS PHARMA, INC.,, 1 BRIDGE PLAZA, SUITE 275, FORT LEE
Signature
/s/ Kenneth Hoberman
Signature date
12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCT transaction

Common Stock

Award

Transaction value
Shares
+35,000
Change %
+26%
Price
$0.000000*
Shares after
168,140
Date
11 Jun 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.

Footnote F2

Includes shares of restricted common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .